Linezolid for the treatment of postneurosurgical infection caused by methicillin-resistant Staphylococcus
- Departments of Anesthesiology and Critical Care Medicine, Uninversity of Tunis El Manar, Tunisia.
- Departments of Neurosurgery, Traumatology and Severe Burns Center, Faculty of Medicine of Tunis, Uninversity of Tunis El Manar, Tunisia.
Departments of Neurosurgery, Traumatology and Severe Burns Center, Faculty of Medicine of Tunis, Uninversity of Tunis El Manar, Tunisia.
DOI:10.25259/SNI_455_2019Copyright: © 2019 Surgical Neurology International This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
How to cite this article: Lotfi Rebai, Nizar Fitouhi, Mohamed Aziz Daghmouri, Kamel Bahri. Linezolid for the treatment of postneurosurgical infection caused by methicillin-resistant Staphylococcus. 08-Nov-2019;10:215
How to cite this URL: Lotfi Rebai, Nizar Fitouhi, Mohamed Aziz Daghmouri, Kamel Bahri. Linezolid for the treatment of postneurosurgical infection caused by methicillin-resistant Staphylococcus. 08-Nov-2019;10:215. Available from: http://surgicalneurologyint.com/surgicalint-articles/9739/
Background: Postneurosurgical infection (PNSI) is a major problem. Linezolid is a bacteriostatic oxazolidinone antibiotic with a highly activity against Gram-positive cocci resistant to methicillin and a good cerebrospinal fluid penetration. The purpose of this study is to evaluate the efficacy of linezolid in the treatment of PNSI caused by methicillin-resistant Staphylococcus (MRS).
Methods: We conducted an observational study for all patients over 14 years old and diagnosed with MRS PNSI. Demographic, clinical, and laboratory information were collected prospectively.
Results: A total of 10 patients with PNSI (6 meningitis, 2 ventriculitis, and 2 subdural empyema) received linezolid. MRS isolated was Staphylococcus aureus in seven cases and Staphylococcus epidermidis in three cases. All isolated microorganisms were susceptible to vancomycin (minimum inhibitory concentration (MIC) = 2 mg/L) and linezolid (MIC = 1). The rate of microbiologic efficacy was 100% for patients with meningitis or ventriculitis. In the case of subdural empyema, focal infection had improved between 14 and 18 days. No adverse effects occurred during this study.
Conclusion: Our results suggest that linezolid as an alternative to vancomycin for the treatment of PNSI caused by MRS with a high rate of efficacy.
Keywords: Linezolid, Methicillin-resistant Staphylococcus, Neurosurgical infection
Postneurosurgical infection (PNSI) is a major problem and frequently requiring high dose and prolonged antibiotic therapy.[
An observational, noncomparative, prospective study was performed at our center, tertiary care teaching hospital, between June 2017 and December 2018. The hospital has a 36-bed neurosurgery ward and six of these beds are in an intensive care unit. Our protocol was approved by the ethical and scientific committee of traumatology and severe Burns Center, Tunisia. Patients were included for the study if they were at least 14 years of age and diagnosed with MRS PNSI. Empirical therapy, consists of vancomycin (60 mg/kg/24 h) in combination with cefotaxime (200–300 mg/kg/24 h), was administered as soon as the infection was suspected and before microbiologic testing result. Linezolid was administered in the standard dosage of 2 × 600 mg/day, after the identification and susceptibility testing of MRS. If the duration of the treatment exceeds 14 days, linezolid intravenous administration is relayed by the oral route at the same dose (600 mg × 2/day). Demographic, clinical, and laboratory information were collected prospectively. Clinical information included procedure surgery, antibiotic combination, duration of treatment, days of hospitalization, and outcomes.
Definition of PNSI
PNSI was diagnosed according to the criteria of the Centers for Disease Control and Prevention,[
CSF was obtained either by lumbar puncture or from extraventricular drainage reservoirs. All CSF samples were analyzed for leukocyte count, glucose, and lactate level and cultivated in aerobic media and anaerobic media. Identification of the etiological agents and susceptibilities to antibiotics was determined by Clinical Laboratory Standards Institute (CLSI) methods.[
A descriptive analysis was performed using SPSS software version 24. Quantitative variables were expressed as the median.
Among 240 patients operated during the study period, 19 had PNSI yielding a total incidence of 7.9%. A total of 10 cases of MRS PNSI were diagnosed. The median age was 48 years (range, 23–71) and 50% of patients were male. Meningitis was the most frequent infection, diagnosed in 6 cases (60%). This was followed by subdural empyema (20%) and ventriculitis (20%). Among the patients with postoperative meningitis, four had undergone surgery for supratentorial tumors, one for posterior fossa tumor, and one for Chiari I decompression. Two cases of ventriculitis occurred after the insertion of external ventricular drain for postoperative hydrocephalus and the patients with subdural empyema had undergone surgery for subdural hematoma. Only four patients received perioperative steroids (patient 2, 3, 4, and 6). Patient demographic data and type of PNSI are summarized in
The most common CSF abnormalities, for meningitis and ventriculitis, were pleocytosis (100%), hypoglycorrhachia (100%), and elevated lactate level (87%). The median CSF leukocyte count was 1224 cells/uL and the median of CSF lactate level was 9.8 mmol/l. CSF Gram stain was positive in 10% and culture was positive in all cases. MRS isolated were Staphylococcus aureus (MRSA) in seven cases and Staphylococcus epidermidis (MRSE) in three cases. Among the patient with PNSI caused by MRSE, two had an external ventricular drain and one had a CSF leakage. All isolated microorganisms were susceptible to vancomycin (minimum inhibitory concentration [MIC] = 2 mg/L), teicoplanin (MIC = 2 mg/L), and linezolid (MIC = 1) according to CLSI criteria [
All patients had been given vancomycin and cefotaxime before receiving linezolid. The median duration of vancomycin administration was 3 days. The median duration of antimicrobial treatment was 18 days (range, 14–42). Patients with MRS meningitis and ventriculitis had received intravenously linezolid for an average of 14 days. Into the two cases of subdural empyema, patients had received intravenously linezolid for 14 days then related by oral linezolid for 14–28 days. During linezolid therapy, two patients had received additional antibiotics for nosocomial pneumonia (patient 2 had received ceftazidime for Pseudomonas aeruginosa pneumonia and patient 4 had received colistin for Acinetobacter baumannii pneumonia) [
Clinical and microbiologic efficacy
All patients with meningitis or ventriculitis had clearance of MRS from the CSF by day 5 of linezolid therapy. In patients with external ventricular catheter (patients 1 and 2), catheter was removed and followed by immediate replacement. In patients with subdural empyema, focal infection had improved on 14 days for patient 8 and on 18 days of linezolid therapy.
There were no in-hospital mortalities in our series and all patients were cured at the end of treatment. There were no severe hematologic, renal, or hepatic toxicity during treatment with linezolid.
Our study has shown that treatment with linezolid is a safe and effective alternative to vancomycin in patient with postneurosurgical ventriculitis, meningitis, and subdural empyemas caused by MRS.
MRS is the most common isolated organism in the PNSI.[
The “gold standard” antimicrobial treatment of PNSI caused by MRS is vancomycin;[
Linezolid, bacteriostatic oxazolidinone antibiotic, has a good penetration into the CSF, with a median CSF/plasma ratio of 0.77 and CFS concentration exceeded the MIC of the Gram-positive bacteria that cause PNSI.[
There are few cases in literature that have examined the efficacy of linezolid in the treatment of subdural empyemas. Maure et al. have treated successfully two cases of MRSA subdural empyema with linezolid as an adjunct to surgical therapy.[
The most common side effects after linezolid administration are gastrointestinal effects (nausea and vomiting) followed by hematological effects (anemia and thrombocytopenia) and lactic acidosis.[
The high consumption of linezolid in the intensive care unit is causing the increase of linezolid-resistant bacteria worldwide. Recently, Rodríguez-Lucas et al. were detected five cases of nosocomial ventriculitis by linezolid-resistant S. epidermidis in a Spanish hospital between 2013 and 2016.[
Our study has some limitations. First, it was monocentric noncomparative observational study that included various PNSIs. Second, the small number of patients can limit our results on the efficacy of linezolid for the treatment of PNSI caused by MRS as well as underestimate the incidence of side effects.
Our results suggest that linezolid as an alternative to vancomycin for the treatment of PNSI caused by MRS with a high rate of efficacy. Orally linezolid may be a very interesting option for early discharge of patients.
1. Bahubali VK, Vijayan P, Bhandari V, Siddaiah N, Srinivas D. Methicillin-resistant Staphylococcus aureus intracranial abscess: An analytical series and review on molecular, surgical and medical aspects. Indian J Med Microbiol. 2018. 36: 97-103
2. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med. 2010. 362: 146-54
3. Chaudhuri A, Martinez-Martin P, Kennedy PG, Andrew Seaton R, Portegies P, Bojar M. EFNS guideline on the management of community-acquired bacterial meningitis: Report of an EFNS task force on acute bacterial meningitis in older children and adults. Eur J Neurol. 2008. 15: 649-59
4. Di Paolo A, Gori G, Tascini C, Danesi R, Del Tacca M. Clinical pharmacokinetics of antibacterials in cerebrospinal fluid. Clin Pharmacokinet. 2013. 52: 511-42
5. Diaz R, Afreixo V, Ramalheira E, Rodrigues C, Gago B. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis. Clin Microbiol Infect. 2018. 24: 97-104
6. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: Results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother. 2005. 49: 5024-32
7. Dryden M, Andrasevic AT, Bassetti M, Bouza E, Chastre J, Baguneid M. Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: A 2014 follow-up survey. Int J Antimicrob Agents. 2015. 45: S1-14
8. French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003. 51: ii45-53
9. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother. 2002. 46: 2723-6
10. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008. 36: 309-32
11. Huang WC, Lee CH, Liu JW. Clinical characteristics and risk factors for mortality in patients with meningitis caused by Staphylococcus aureus and vancomycin minimal inhibitory concentrations against these isolates. J Microbiol Immunol Infect. 2010. 43: 470-7
12. Kestle JR, Garton HJ, Whitehead WE, Drake JM, Kulkarni AV, Cochrane DD. Management of shunt infections: A multicenter pilot study. J Neurosurg. 2006. 105: 177-81
13. Kumari VH, Babu AR, Srinivas D, Siddaiah N, Somanna S. Methicillin-resistant Staphylococcus aureus central nervous system infections analysis and outcome. Br J Neurosurg. 2015. 29: 413-8
14. Luque S, Grau S, Alvarez-Lerma F, Ferrández O, Campillo N, Horcajada JP. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. Int J Antimicrob Agents. 2014. 44: 409-15
15. .editors. M100-S24: Performance Standards for Antimicrobial Susceptibility Testing. p.
16. Martín-Gandul C, Mayorga-Buiza MJ, Castillo-Ojeda E, Gómez-Gómez MJ, Rivero-Garvía M, Gil-Navarro MV. Sequential antimicrobial treatment with linezolid for neurosurgical infections: Efficacy, safety and cost study. Acta Neurochir (Wien). 2016. 158: 1837-43
17. Maure B, Martínez-Vázquez C, Argibay A, Pérez-Veloso M, Rodríguez Fernández MJ, Sopeña B. Linezolid in postneurosurgical infections. Infection. 2008. 36: 82-3
18. McClelland S, Hall WA. Postoperative central nervous system infection: Incidence and associated factors in 2111 neurosurgical procedures. Clin Infect Dis. 2007. 45: 55-9
19. Namvar AE, Bastarahang S, Abbasi N, Ghehi GS, Farhadbakhtiarian S, Arezi P. Clinical characteristics of Staphylococcus epidermidis A systematic review. GMS Hyg Infect Control. 2014. 9: Doc23-
20. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010. 23: 858-83
21. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother. 2007. 41: 296-308
22. Plosker GL, Figgitt DP. Linezolid: A pharmacoeconomic review of its use in serious gram-positive infections. Pharmacoeconomics. 2005. 23: 945-64
23. Rodríguez-Lucas C, Fernández J, Boga JA, López-Amor L, Forcelledo L, Lázaro-López E. Nosocomial ventriculitis caused by a meticillin-and linezolid-resistant clone of Staphylococcus epidermidis in neurosurgical patients. J Hosp Infect. 2018. 100: 406-10
24. Rupprecht TA, Pfister HW. Clinical experience with linezolid for the treatment of central nervous system infections. Eur J Neurol. 2005. 12: 536-42
25. Schwameis R, Fille M, Manafi M, Zeitlinger M, Sauermann R. Enhanced activity of linezolid against Staphylococcus aureus in cerebrospinal fluid. Res Microbiol. 2012. 163: 157-60
26. Sipahi OR, Bardak S, Turhan T, Arda B, Pullukcu H, Ruksen M. Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: A series of 17 cases. Scand J Infect Dis. 2011. 43: 757-64
27. Sipahi OR, Bardak-Ozcem S, Turhan T, Arda B, Ruksen M, Pullukcu H. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus meningitis. Surg Infect (Larchmt). 2013. 14: 357-62
28. Villani P, Regazzi MB, Marubbi F, Viale P, Pagani L, Cristini F. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother. 2002. 46: 936-7
29. Zhan R, Zhu Y, Shen Y, Shen J, Tong Y, Yu H. Post-operative central nervous system infections after cranial surgery in China: Incidence, causative agents, and risk factors in 1,470 patients. Eur J Clin Microbiol Infect Dis. 2014. 33: 861-6